- |||||||||| Reimbursement, US reimbursement, Journal, Medicare, Checkpoint inhibition, Metastases: Factors Associated with Adoption of Immune Checkpoint Inhibitor Treatment for Advanced Melanoma: A SEER-Medicare Cohort Study. (Pubmed Central) - Aug 12, 2024
These associations were diminished in more recent years (no association with sex, medical oncologist density, Charlson comorbidity score, and association with only the oldest age group in years 2015-2017). We found significant sex- and age-related differences in initiation among SEER-Medicare beneficiaries with stage III or stage IV melanoma, which appear to be improving over time.
- |||||||||| Gazyva (obinutuzumab) / Roche, Biogen
Journal: Chronic hepatitis E virus-induced spinal cord atrophy in a patient with chronic lymphatic leukemia: a case report and interdisciplinary management proposal. (Pubmed Central) - Aug 12, 2024
Treatment with obinutuzumab resulted in acute bowel and urinary retention and a further deterioration of motor skills, prompting the discontinuation of obinutuzumab...The challenges faced in diagnosing new neurological symptoms in patients undergoing immunosuppressive cancer treatment underscore the need for an interdisciplinary diagnostic approach that includes HEV testing. We propose a diagnostic pathway for future validation in immunocompromised cohorts presenting with neurological symptoms, emphasizing its potential to enhance clinical outcomes.
- |||||||||| Rituxan (rituximab) / Roche
Journal: Rituximab-Associated Liver Toxicity Without Known Viral Reactivation. (Pubmed Central) - Aug 12, 2024
A major adverse effect of rituximab is hepatocellular injury attributed to hepatitis B viral reactivation, necessitating viral titers before treatment. In this case report, we illustrate the rare presentation of a patient with marginal zone B-cell lymphoma who experienced symptomatic liver injury with a peak 15-fold aminotransferase elevation following his first dose of rituximab, without evidence of viral reactivation.
- |||||||||| Nplate (romiplostim) / Amgen, Kyowa Kirin
Journal: Idiopathic Thrombocytopenic Purpura (ITP) Complicated by a Hemorrhagic Ovarian Cyst and Hemoperitoneum: A Case Report. (Pubmed Central) - Aug 12, 2024
The patient benefited from fluid resuscitation, blood transfusion, and corticosteroid therapy; then, the patient's condition improved. This case highlights the complications associated with managing ITP, emphasizing the importance of personalizing therapy regimens through regular monitoring to improve the balance of benefits and risk, resulting in a comprehensive treatment for chronic patients suffering from ITP.
- |||||||||| Opdivo (nivolumab) / BMS
Journal: Nivolumab-Induced Diabetic Ketoacidosis: A Case Report. (Pubmed Central) - Aug 12, 2024
The patient presented with symptoms of hyperglycemia, metabolic acidosis, and ketosis after receiving nivolumab therapy for 12 cycles. Prompt recognition and management of nivolumab-induced DKA are crucial to prevent complications and ensure patient safety.
- |||||||||| Rituxan (rituximab) / Roche
Journal: Duodenal-Type Follicular Lymphoma. (Pubmed Central) - Aug 12, 2024
This rare condition typically presents with minimal clinical symptoms and has a favorable prognosis. Treatment options for duodenal-type follicular lymphoma include a watch-and-wait strategy, rituximab monotherapy, and radiotherapy.
- |||||||||| Retrospective data, Journal: A network meta-analysis of efficacy and safety for first-line and maintenance therapies in patients with unresectable colorectal liver metastases. (Pubmed Central) - Aug 12, 2024
Resection or ablation (R/A)+SingleCT, S1, and Cetuximab + intensified fluorouracil-based combination chemotherapy (ICTFU) were identified as the best treatments...The top three treatments were: Atezolizumab + Bevacizumab + fluorouracil-based combination chemotherapy (CTFU), TAS-102+bevacizumab, Bevacizumab + ICTFU...Regarding maintenance treatment, Bevacizumab + SingleCT and Adavosertib were the best options for OS and PFS, respectively...Monotherapy may be preferred choice for maintenance treatment. Combination therapy resulted in more SAEs when compared to standard chemotherapy.
- |||||||||| Rituxan (rituximab) / Roche
Journal, Combination therapy, Checkpoint inhibition: Combination therapy of targeting CD20 antibody and immune checkpoint inhibitor may be a breakthrough in the treatment of B-cell lymphoma. (Pubmed Central) - Aug 12, 2024
Hotspots in this field still focus on the efficacy of rituximab in treating non-Hodgkin's lymphoma and the pathogenesis of lymphoma Application of generation CD-20 antibodies or molecule inhibitors in clinical research and cellular therapy/immunotherapy, such as CAR-T and PDL1/PD1 were the emerging research topics. This study provides essential information and the tendency of the CD20-targeting antibody therapy in lymphoma by using bibliometric and visual methods, which would provide helpful references for clinical experiments and basic scientific research.
- |||||||||| Imfinzi (durvalumab) / AstraZeneca
Journal: Durvalumab-Induced Triple-M Syndrome. (Pubmed Central) - Aug 12, 2024
This study identifies a novel unreported adverse effect-bilateral vocal cord and velopalatine paralysis-associated with atezolizumab use. Triple-M syndrome is a rare immune-related adverse effect, which has been noted in other immune checkpoint inhibitors, but less so with durvalumab specifically.Immunotherapy-induced myositis, myocarditis and myasthenia can occur in isolation or, rarely, in association as a syndrome.This case demonstrates the potentially life-threatening nature of this entity, the need for early recognition, and multi-specialist teamwork to ensure good outcome.
- |||||||||| Rituxan (rituximab) / Roche
Journal: Vascular Threads and Nephron Nests: Exploring the Association Between Takayasu Arteritis and Membranous Nephropathy. (Pubmed Central) - Aug 12, 2024
Triple-M syndrome is a rare immune-related adverse effect, which has been noted in other immune checkpoint inhibitors, but less so with durvalumab specifically.Immunotherapy-induced myositis, myocarditis and myasthenia can occur in isolation or, rarely, in association as a syndrome.This case demonstrates the potentially life-threatening nature of this entity, the need for early recognition, and multi-specialist teamwork to ensure good outcome. Membranous nephropathy (MN) and Takayasu arteritis (TA) have distinct clinical presentations; therefore, diagnosing coexisting MN and TA is challenging, which may lead to delayed diagnoses.A multidisciplinary approach with tailored treatments is essential for prompt diagnosis and optimal management.Comprehensive follow-up studies are vital to understand the pathogenesis of this rare amalgamation, refine targeted treatment strategies and potentially improve overall prognosis.
- |||||||||| FS120 / Sino Biopharm
Journal: IFN-? production by functionally reprogrammed Treg cells promotes anti-tumor efficacy of OX40/CD137 bispecific agonist therapy. (Pubmed Central) - Aug 12, 2024
Importantly, conditional deletion of Ifng in Foxp3+ Treg cells and their progeny partially reverses the anti-tumor efficacy of OX40/CD137 bispecific agonist therapy, revealing that reprogramming of Treg cells into IFN-?-producing cells contributes to the efficacy of OX40/CD137 bispecific agonists. These findings provide insights into mechanisms by which bispecific agonist therapies targeting co-stimulatory receptors highly expressed by Treg cells potentiate anti-tumor immunity in mouse models.
- |||||||||| Rituxan (rituximab) / Roche
Retrospective data, Journal: Rituximab alone is as effective as associated with steroids on naive patients with generalized myasthenia gravis. (Pubmed Central) - Aug 12, 2024
These findings provide insights into mechanisms by which bispecific agonist therapies targeting co-stimulatory receptors highly expressed by Treg cells potentiate anti-tumor immunity in mouse models. We suggest that RTX alone is as effective as RTX-CS in MG patients, indicating that avoiding steroids could reduce side effects, decrease rescue therapies, and not affect MG outcomes.
- |||||||||| samatatug zovodotin (XB002) / Exelixis
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of XB002 in Subjects With Solid Tumors (JEWEL-101) (clinicaltrials.gov) - Aug 11, 2024
P1, N=573, Active, not recruiting,
Trial primary completion date: Oct 2028 --> Feb 2029 Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Feb 2025 | Trial primary completion date: Jun 2024 --> Feb 2025
- |||||||||| ASP2138 / Astellas
Trial completion date, Combination therapy, Monotherapy, Metastases: A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer (clinicaltrials.gov) - Aug 11, 2024
P1, N=305, Recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Feb 2025 | Trial primary completion date: Jun 2024 --> Feb 2025 Trial completion date: Jun 2026 --> Dec 2026
- |||||||||| Jemperli (dostarlimab-gxly) / GSK, Zejula (niraparib) / GSK, J&J
Enrollment closed, Phase classification, Trial completion date, Trial primary completion date, PD(L)-1 companion diagnostic: OPAL: A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer (clinicaltrials.gov) - Aug 11, 2024
P2, N=125, Active, not recruiting,
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Phase classification: P1b/2 --> P2 | Trial completion date: Mar 2026 --> Apr 2027 | Trial primary completion date: Aug 2024 --> Aug 2025
- |||||||||| CX-801 / CytomX
Enrollment open, Combination therapy, Monotherapy, Metastases: KEYNOTE-F95: First In Human Study of CX-801 in Advanced Solid Tumors (clinicaltrials.gov) - Aug 11, 2024
P1, N=121, Recruiting,
Recruiting --> Active, not recruiting | Phase classification: P1b/2 --> P2 | Trial completion date: Mar 2026 --> Apr 2027 | Trial primary completion date: Aug 2024 --> Aug 2025 Not yet recruiting --> Recruiting
- |||||||||| Tavalisse (fostamatinib) / Rigel
Clinical data, Observational data, Retrospective data, Journal, Real-world evidence, Real-world: Real-world clinical outcomes with fostamatinib for the treatment of refractory chronic immune thrombocytopenia: a single-center experience. (Pubmed Central) - Aug 11, 2024
Subgroups who had higher rates of durable responses included those who had received two to three prior lines of therapy (40%), splenectomized patients (50%), and those who had not received prior rituximab (55%). Fostamatinib therapy in a real-world population of patients with heavily pretreated ITP led to a durable response in a third of patients, which was maintained for most responders.
- |||||||||| Imfinzi (durvalumab) / AstraZeneca
Patient-Reported Outcomes (PROs) With Consolidation Durvalumab Versus Placebo Following cCRT in Limited-Stage SCLC: ADRIATIC (20D) - Aug 11, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2788;
P3
Similar improvement rates were reported in both arms for prespecified key subscales (Table) and other subscales; the only difference observed was for chest pain (LC13; 67.3% versus 47.8% for durvalumab versus placebo [odds ratio 2.28; 95% CI 1.08?4.95]). Conclusions : In ADRIATIC, treatment with durvalumab for up to 2 years improved survival outcomes versus placebo without a clinically meaningful impact on PROs for GHS/QoL, functioning or symptoms, further supporting consolidation durvalumab as a new standard of care in LS-SCLC.
- |||||||||| Imfinzi (durvalumab) / AstraZeneca
Neoadjuvant Concurrent Chemo-Immuno-Radiation Therapy Followed by Surgery for Stage III-N2 NSCLC: SQUAT Trial (WJOG 12119L) (32AB) - Aug 11, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2766;
One patient had a treatment-related death due to myocardial infarction and interstitial pneumonia. Conclusions : Our results demonstrated the impact of adding RT to neoadjuvant chemo-immunotherapy on long-term outcomes of patients with resectable stage IIIA-B N2 NSCLC for the first time.This treatment regimen shows high pathologic efficacy and feasibility, and may become a promising treatment for selected patients with stage II-III NSCLC.
- |||||||||| Opdivo (nivolumab) / BMS
Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC: Patient-Level Data Analysis of CheckMate 77T vs CheckMate 816 (Plenary Hall) - Aug 11, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2755;
Conclusions : In this landmark IPTW EFS analysis, perioperative nivolumab showed EFS improvement vs neoadjuvant nivolumab in patients with resectable NSCLC, including those with PD-L1 <1% or without pCR. While results should be interpreted with caution given the limitations of propensity score weighted analysis, this is the first individual patient-level data cross-trial analysis of phase 3, international, randomized trials to assess the contribution of the adjuvant phase of a perioperative immunotherapy-based regimen, further supporting perioperative nivolumab as a treatment option for patients with resectable NSCLC.
- |||||||||| Imfinzi (durvalumab) / AstraZeneca
Neocoast-2: Efficacy and Safety of Neoadjuvant Durvalumab (D) + Novel Anticancer Agents + CT and Adjuvant D (Plenary Hall) - Aug 11, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2754;
P2
Treatments in all arms led to improvementsin mPR rates along with a manageable safety profile and surgical ratescomparable to currently approved neoadjuvant and perioperativeimmunotherapy-based regimens (Forde NEJM 2022; Wakelee NEJM 2023). This is the first global Ph2 platform study showing encouragingefficacy and a manageable safety profile of an ADC in the neoadjuvant NSCLCsetting.
- |||||||||| Imfinzi (durvalumab) / AstraZeneca
Perioperative Durvalumab for Resectable NSCLC (R-NSCLC): Updated Outcomes from the Phase 3 AEGEAN Trial (20A) - Aug 11, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2747;
P3
Maximum grade 3/4 AE rates were similar between arms during the overall period and occurred in 15.4% and 10.6% of patients during the adjuvant period ( Table ). Conclusions : These findings, based on 18 months additional follow-up since the primary EFS analysis, further support perioperative durvalumab as a new treatment option for patients with R-NSCLC.
|
